Form 8-K
Material Company Update
2026-04-08
REGN filed 8-K — material company event
REGENERON PHARMACEUTICALS, INC. filed an 8-K with the SEC reporting a material event. Filing excerpt: XBRL Viewer
Latest SEC filings for Regeneron Pharmaceuticals, Inc. (REGN) explained in plain English: insider buying and selling (Form 4), proposed insider sales (Form 144), material company events (8-K), and quarterly & annual reports (10-Q / 10-K). Sourced directly from SEC EDGAR.
REGENERON PHARMACEUTICALS, INC. filed an 8-K with the SEC reporting a material event. Filing excerpt: XBRL Viewer
RYAN ARTHUR F, listed as Director at REGENERON PHARMACEUTICALS, INC., reported an open-market sale of 100 REGN shares in a Form 4 filing. This is a confirmed insider sale, not just a proposed sale notice.
RYAN ARTHUR F, listed as Director at REGENERON PHARMACEUTICALS, INC., reported an open-market sale of 100 REGN shares in a Form 4 filing. This is a confirmed insider sale, not just a proposed sale notice.
Zoghbi Huda Y, listed as Director at REGENERON PHARMACEUTICALS, INC., reported an open-market sale of 1,638 REGN shares in a Form 4 filing. This is a confirmed insider sale, not just a proposed sale notice.
Zoghbi Huda Y filed a Form 144 with the SEC indicating intent to sell REGN (REGENERON PHARMACEUTICALS, INC.) shares. Form 144 reflects a proposed sale, not a completed transaction. The actual execution, if any, would typically appear later in a Form 4.
Pitofsky Jason, listed as SVP Controller at REGENERON PHARMACEUTICALS, INC., reported an open-market sale of 2,036 REGN shares in a Form 4 filing. This is a confirmed insider sale, not just a proposed sale notice.
RYAN ARTHUR F, listed as Director at REGENERON PHARMACEUTICALS, INC., reported an open-market sale of 100 REGN shares in a Form 4 filing. This is a confirmed insider sale, not just a proposed sale notice.
Arthur F. Ryan filed a Form 144 with the SEC indicating intent to sell REGN (REGENERON PHARMACEUTICALS, INC.) shares. Form 144 reflects a proposed sale, not a completed transaction. The actual execution, if any, would typically appear later in a Form 4.
Pitofsky Jason filed a Form 144 with the SEC indicating intent to sell REGN (REGENERON PHARMACEUTICALS, INC.) shares. Form 144 reflects a proposed sale, not a completed transaction. The actual execution, if any, would typically appear later in a Form 4.
REGENERON PHARMACEUTICALS, INC. filed its annual report with the SEC. This report includes audited financial statements, business overview, risk factors, and management discussion.
REGENERON PHARMACEUTICALS, INC. filed an 8-K with the SEC reporting a material event. Filing excerpt: XBRL Viewer
REGENERON PHARMACEUTICALS, INC. filed an 8-K with the SEC reporting a material event. Filing excerpt: XBRL Viewer
Bassler Bonnie L, listed as Director at REGENERON PHARMACEUTICALS, INC., reported an open-market sale of 1,500 REGN shares in a Form 4 filing. This is a confirmed insider sale, not just a proposed sale notice.
Bassler Bonnie L filed a Form 144 with the SEC indicating intent to sell REGN (REGENERON PHARMACEUTICALS, INC.) shares. Form 144 reflects a proposed sale, not a completed transaction. The actual execution, if any, would typically appear later in a Form 4.
Zoghbi Huda Y (Director) filed a Form 4 covering compensation-related activity such as stock awards, option exercises, conversions, or tax withholding. These filings are usually neutral.